PPIX

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
FDA, Research, IRON, Glycine, Erythropoiesis, Food, EPP, PV, Sodium- and chloride-dependent glycine transporter 1, G&A, AURORA, Iron, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ruxolitinib, Light, Porphyria, Inflammation, Poster, Sunlight, Society, ASH, Development, Photosensitivity, Hematology, Quality of life, Phase 10, Anemia, PPIX, Safety, MF, XLP, Pain, Patient, Administration, Polycythemia, Rare-earth element, Pharmaceutical industry, Vaccine, Disc

Third Quarter 2023 Financial Results:

Key Points: 
  • Third Quarter 2023 Financial Results:
    Cash Position: Cash and cash equivalents were $370.5 million as of September 30, 2023, which are expected to fund our operational plans well into 2026.
  • Research and Development Expenses: R&D expenses were $14.4 million for the quarter ended September 30, 2023, as compared to $7.9 million for the quarter ended September 30, 2022.
  • General and Administrative Expenses: G&A expenses were $4.5 million for the quarter ended September 30, 2023, as compared to $2.6 million for the same period in 2022.
  • Net Loss: Net loss was $14.1 million for the quarter ended September 30, 2023, as compared to $16.2 million for the third quarter of 2022.

Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates

Retrieved on: 
Thursday, November 2, 2023
IRON, EPP, AURORA, Ruxolitinib, Society, Sunlight, ASH, Interim, Protoporphyrin IX, Anemia, PPIX, Exposition, Pain, Patient, Pharmaceutical industry, Disc

“We look forward to presenting updated interim data from all patients enrolled in the BEACON study at the upcoming ASH meeting, as well as preliminary clinical data from initial cohorts of both DISC-0974 anemia studies.” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc.

Key Points: 
  • “We look forward to presenting updated interim data from all patients enrolled in the BEACON study at the upcoming ASH meeting, as well as preliminary clinical data from initial cohorts of both DISC-0974 anemia studies.” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc.
  • “In addition, we’re pleased to announce the full enrollment of both the BEACON and AURORA studies of bitopertin in patients with EPP.
  • The full abstracts are now available through the ASH conference website.
  • Please register for management’s webcast on the Events and Presentations page of Disc’s website (https://ir.discmedicine.com/).

Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA

Retrieved on: 
Saturday, June 10, 2023
PPIX, Sodium- and chloride-dependent glycine transporter 1, LSE, Disc, Biotechnology, Quality of life, Congress, Patient, Erythropoietic protoporphyria, EHA, XLP, Bitopertin, Photosensitivity, Safety, Pharmaceutical industry, EPP

The initial trial data from the BEACON study demonstrated consistent decreases in protoporphyrin IX (the disease-causing metabolite in EPP), significant increases in reported sunlight tolerance and improvements in measures of patient quality of life.

Key Points: 
  • The initial trial data from the BEACON study demonstrated consistent decreases in protoporphyrin IX (the disease-causing metabolite in EPP), significant increases in reported sunlight tolerance and improvements in measures of patient quality of life.
  • The BEACON trial is a randomised, open-label, parallel-arm trial enrolling up to 22 patients with EPP or XLP at trial sites in Australia.
  • Robert Lyne, CEO of Arix Bioscience, said: “We are very encouraged by the positive data from the BEACON trial.
  • We look forward to supporting Disc Medicine as they continue to advance the BEACON study through clinical development.

Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

Retrieved on: 
Friday, June 9, 2023
EPIQ, Sodium- and chloride-dependent glycine transporter 1, Protoporphyrin IX, European Hematology Association, Metallicity, Disc, Week, EPP, Bitopertin, Quality of life, First grade, Pain, Congress, Sunlight, IRON, Patient, Erythropoietic protoporphyria, EHA, XLP, Photosensitivity, Poster, Safety, Disease, Pharmaceutical industry, Medical device, Sewage treatment, PPIX

The initial trial data demonstrated consistent decreases in PPIX, significant increases in reported sunlight tolerance and improvements in measures of patient quality of life.

Key Points: 
  • The initial trial data demonstrated consistent decreases in PPIX, significant increases in reported sunlight tolerance and improvements in measures of patient quality of life.
  • “We’re delighted to share these initial, positive data from BEACON, which provide the first clinical evidence supporting our therapeutic hypothesis of bitopertin in EPP.
  • Due to batch processing of samples, the data cutoff for PPIX data was April 7, 2023.
  • Management will host a call to review the presented data on Friday, June 9th at 7:30 am ET.

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

Retrieved on: 
Thursday, May 11, 2023
PPIX, Abstract, European Hematology Association, EPP, AURORA, Quality of life, Congress, IRON, Patient, Randomness, EHA, Bitopertin, Photosensitivity, Safety, Pharmaceutical industry, Erythropoietic protoporphyria

The presentation will report initial results from BEACON, the Phase 2, randomized, open‐label, parallel arm trial of bitopertin in Erythropoietic Protoporphyria (EPP) that is ongoing in Australia.

Key Points: 
  • The presentation will report initial results from BEACON, the Phase 2, randomized, open‐label, parallel arm trial of bitopertin in Erythropoietic Protoporphyria (EPP) that is ongoing in Australia.
  • Additionally, an abstract outlining the study design of AURORA, a Phase 2, randomized double-blind, placebo-controlled trial of bitopertin in EPP will be published in the EHA Abstract Book.
  • Management will host a call to review the presented data on Friday, June 9th at 7:30 am ET.
  • Title: Initial Data from the BEACON Trial: A Phase 2, Randomized, Open‐label Trial of Bitopertin in Erythropoietic Protoporphyria
    Title: Study Design of the AURORA Trial: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of Bitopertin in Erythropoietic Protoporphyria

Disc Medicine Announces Oral Presentation on Bitopertin at the 63rd American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 11, 2021
Society, Degenerative disease, Heme, Sodium- and chloride-dependent glycine transporter 1, Boston Children's Hospital, Glycine, Hospital, Disease, Roche, ASH, Bitopertin, Hematologic disease, Lists of diseases, Treatment, Multimedia, PPIX, XLP, Exposition, Medicine, EPP, Erythropoiesis, Development, Erythropoietic protoporphyria, Hope, Patient, Pharmaceutical industry

Disc Medicine is planning to develop bitopertin as a potential treatment for patients with EPP and XLP as well as a range of other hematologic diseases.

Key Points: 
  • Disc Medicine is planning to develop bitopertin as a potential treatment for patients with EPP and XLP as well as a range of other hematologic diseases.
  • Bitopertin is an experimental agent and is not approved for use as a therapy in any jurisdiction worldwide.
  • Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders.
  • Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease.

ProPhotonix Extends COBRA HyperSpec range to offer hyperspectral SWIR illumination from 950nm to 1750nm

Retrieved on: 
Wednesday, November 3, 2021
Safety, SWIR, Recycling, Technology, LED, Quality control, Food industry, Eye, Food, United Kingdom, COBRA, Pressure, Light, Solution, Common Lisp HyperSpec, Acquisition, PPIX, Pulse, London Stock Exchange, GUI, Telescopic sight

For example, in textile recycling, the COBRA HyperSpec SWIR configuration can be used to differentiate between manmade materials like polyester and plant-based materials such as cotton.

Key Points: 
  • For example, in textile recycling, the COBRA HyperSpec SWIR configuration can be used to differentiate between manmade materials like polyester and plant-based materials such as cotton.
  • Commenting on the new COBRA HyperSpec product, Simon Stanley said:
    "Our launch of the SWIR COBRA HyperSpec LED Line Light gives companies more flexibility to test this new technology and better define their specification.
  • The COBRA HyperSpec SWIR is the latest addition to the ProPhotonix COBRA Line Light product range.
  • The COBRA MultiSpec and HyperSpec products offer up to 12 wavelengths in a compact, completely configurable platform allowing for optimal image acquisition.